| Lisa Deuel Baker, MD | |
|
1 S Prospect St, Burlington, VT 05401-3456 | |
| (802) 847-4589 | |
| Not Available |
| Full Name | Lisa Deuel Baker |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 10 Years |
| Location | 1 S Prospect St, Burlington, Vermont |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053730408 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Univ. Of Vermont - Fletcher Allen Health Care | Burlington, VT | Hospital |
| Champlain Valley Physicians Hospital Medical Ctr | Plattsburgh, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Vermont Medical Center Inc | 3779491071 | 994 |
| Champlain Valley Physicians Hospital Medical Center | 2769396878 | 233 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.
People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.
› Verified 4 days ago
| Entity Name | University Of Vermont Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659309615 PECOS PAC ID: 3779491071 Enrollment ID: O20040406001047 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.
People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Deuel Baker, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Lisa Deuel Baker, MD 1 S Prospect St, Burlington, VT 05401-3456 Ph: (802) 847-4589 |
News Archive
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.
People who have Alzheimer's disease may be less likely to develop cancer, and people who have cancer may be less likely to develop Alzheimer's disease, according to a new study published in the December 23, 2009, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.
AstraZeneca Canada announces the recently approved indication for IRESSA(R), a once-daily oral targeted therapy for the first-line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In conjunction with this approval, AstraZeneca is also announcing the availability of a diagnostic test which can now determine a patient's EGFR mutation status, representing a new era in personalized lung cancer treatment in Canada.
GlaxoSmithKline today confirmed that it has notified regulatory authorities of the presence of material from a virus called PCV-1 in its oral rotavirus vaccine, Rotarix™. PCV-1 does not multiply in humans and is not known to cause illness in humans.
› Verified 4 days ago
Rebecca Burch, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4589 | |
Dr. Dhruv Shah, DO Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-0000 | |
Judith L Lewis, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Avenue, Fletcher Allen Health Care, Burlington, VT 05401 Phone: 804-847-2791 Fax: 802-847-2733 | |
Ms. Laura Lynn Sponseller, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 111 Colchester Ave, Fahc Department Of Psychiatry, Patrick 4, Burlington, VT 05401 Phone: 802-829-9645 | |
Dr. Robert A Pierattini, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1 S Prospect St, Burlington, VT 05401 Phone: 802-847-4560 Fax: 802-847-8747 | |
Dr. Edward George Boyer Iv, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 111 Colchester Ave, Burlington, VT 05401 Phone: 802-847-4589 |